Log in to save to my catalogue

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_umu_150728

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Hereditary transthyretin amyloidosis is caused by the deposition of misfolded transthyretin proteins in peripheral nerves and other tissues. This phase 3 trial tested patisiran, a small interfering RNA targeting transthyretin messenger RNA, to treat the disease.

Alternative Titles

Full title

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_DiVA_org_umu_150728

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_umu_150728

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1716153

How to access this item